ImmunologyO-18-14IL-18 is an important target for development of immune modulator inpulmonary diseasesDo-Hyun Kim¹ , ², Min-Jong Kang³, Je-min Choi¹ , ² , *¹Department of Life Science, Hanyang University, ²Hanyang Biomedical Research Institute, Seoul133-791, Korea and ³Section of Pulmonary and Critical Care Medicine, Yale University School ofMedicine, CT 06520, USAInterleukin-18 (IL-18), originally identified as IFN-γinducing factor and it was known toplay important roles in various autoimmune and allergic diseases such as COPD, RA,and asthma, etc. However the importance of IL-18 as a target of immune modulator, isnot much appreciated. Here we investigated that IL-18 induces Th1, 2 and 17inflammation in the lung including alveolar destruction and airway inflammation in lungspecific IL-18 TG mice. To develop IL-18 antagonizing immune modulator, we havegenerated novel CPP conjugated IL-18BP chimeric protein (CPP-mIL-18BPc). IL-18BP isa naturally occurring IL-18 antagonizing protein and CPP-mIL-18BPc efficiently deliveredinto cells time and dose dependent manner. Treatment of CPP-mIL-18BPc inhibitedmacrophage activation potentially suggesting that IL-18 targeting immune modulatorwould be a attractive novel therapeutic approach to regulate immune responses. Theseresults demonstrate that IL-18 plays an important roles in lung destruction and pulmonaryinflammation and CPP-mIL-18BPc can be a novel immune modulatory protein in variousinflammatory diseases. [Supported by grants from KRF 20<strong>10</strong>-<strong>00</strong>25389]O-18-17Anti-inflammatory effects of SHRC in DSS-induced colitis modelHye - Eun Choi¹ , ², Seung jun Lee¹ , ², Hyo Jin An¹and Kyung-Tae Lee¹ , ² , *¹Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University 1 Hoegidong,Dongdaemun-gu, Seoul 130-701, Korea, ²Department of Life and NanopharmaceuticalScience, College of Pharmacy, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, KoreaIn this study, we studied that alleviatory effect of SHRC (saponin- high fraction of Rubuscoreanus Miquel) in DSS-induced colitis model and the molecular mechanisms of SHRCfor its anti-inflammatory properties in LPS-induced RAW 264.7 macrophage cells. In DSScolitis model, the DAI score and detection of MPO accumulation revealed SHRCsignificantly inhibited loss of body weight, suppression of diarrhea and bleeding, andinfiltration of macrophage. Moreover, H&E staining also indicated SHRC suppressed thethickness of muscle layer, edema, mucosal damage by DSS. In addition, SHRCdecreased the nitric oxide (NO) production in DSS-induced colitis model. SHRCattenuated the DSS-induced pro-inflammatory cytokines. SHRC suppressed the LPSinducedNO and prostaglandin E2 (PGE2) production and pro- inflammatory cytokines.We determined that SHRC inhibited the transcriptional activity of nuclear factor-kappa B(NF-κB) and its translocation to the nucleus though the suppression of inhibitory kappa Bα(IκBα) phosphorylation in LPS-activated RAW 264.7 cells. Taken together, these resultssuggest that the anti-inflammatory effect of SHRC is achieved through the inhibition ofiNOS, COX-2, pro-inflammatory cytokines expression via suppression of NF-κB activationin vivo and in vitro.O-18-15Farnesoic O-methytransferase-like protein of Tenebrio molitor larvae isspecifically recruited on Mycobacterium marinum cellsYong-In So¹, Lili Zheng¹, Ye-Rang Heo¹, Seong-Min Kang¹, Yeo-Jin Won¹, Dong-Jun Jung¹, Yong-Hun Jo¹, Kenji Kurokawa¹, Ki-Hye Kim², Eun-kyeong Jo²andBok-Leul Lee¹¹The national Research Laboratory of Defense Proteins, College of Pharmacy, Pusan NationalUniversity, Kumjeong Ku, Busan 609-735, Korea, ²Department of Microbiology, College ofMedicine, Chungnam National University, 6 Munhwa-dong, Jungku, Daejeon 301-747, KoreaMycobacterium tuberculosis is a major intracellular pathogen of humans, with anestimated one-third of the global population being latently infected, 2-3million deathsannually from tuberculosis, and an increasing numbers of multidrug-resistant strains totuberculosis. Mycobacterium marinum, a close relative of Mycobacterium tuberculosis isbeing used to study mycobacterial pathogenesis. Here, we found that antimicrobialpeptides (AMPs) were induced in Tenebrio molitor by injection of Mycobacteriummarinum into Tenebrio larvae. We also observed that a 19 kDa protein originated fromTenebrio hemocytes specifically recruited on the Mycobacterium marinum cell surface.When we obtained cDNA of 19 kDa protein, it showed high homology with that offarnesoid O-methyltransferase-like protein (OMT) of Tribolium cataneum. When dsRNAof Tenebrio OMT was injected into T. molitor larvae, OMT gene expression was knockdown.Now we are determining the biological function of OMT protein duringMycobacterium marinum infection.O-18-18Anti-wall teichoic acid antibodies in human serum specifically activatehuman classical complement pathwayDong-Jun Jung, Jang-Hyun An, In-Kyung Seo, Min-Su Kim, Kyoung-Hwa Ryu,Yong-In So, Yong-Hun Jo, Kenji Kurokawa and Bok Luel LeeFrom the National Research Laboratory of Defense Proteins, College of Pharmacy, Pusan NationalUniversity, Busan 609-735, KoreaStaphylococcus aureus are covered with several cell wall components, such aspeptidoglycan (PGN), lipoteichoic acid (LTA), and wall teichoic acid (WTA). Thesemolecules are known to function as ligand molecules during activation of innate immuneresponses. But, their exact biological roles are not clearly determined. We recentlydemonstrated that WTA of S. aureus is a functional ligand of mannose-binding lectin(MBL), a serum mediator of lectin complement pathway However, the molecular functionof S. aureus WTA during human complement activation is not clearly demonstrated. Toexamine the function of WTA, we purified anti-WTA antibodies and anti-LTA antibodiesfrom human intravenous immunoglobulin (IVIG) and then checked the abilities bymeasuring C4 and C3 deposition. Anti-WTA antibodies specifically deposited C4 on S.aureus cell surface, but not anti-LTA antibodies, suggesting that anti-WTA activateclassical complement pathway. To further confirm whether anti-LTA antibodies canactivate alternative complement pathway, we examined the C3 deposition using C2deficient and factor B-deficient serums. These results demonstrated that the cell wallcomponents of S. aureus function as critical ligand molecules during human complementactivation.O-18-16Comparison of immunological properties about monomeric dap-typepeptidoglycan between tenebrio molitor and trbolium castaneum by rnainterference experimentJun-Ho Chae, Bing Zhang, Eun-Han Park, Jang-Hyun An, Dong-Jun Jung, Yong-InSo, Yong Hun Jo, Kenji Kurokawa and Bok Luel LeeFrom the National Research Laboratory of Defense Proteins, College of Pharmacy, Pusan NationalUniversity, Busan 609-735, KoreaBacteria peptidoglycan(PGN), a bacterial cell wall component, is known to be recognizedby peptidoglycan recognition protein(PGRP), which are acting as pattern recognitionmolecules during insect innate immunity. Different types of PGNs are known to berecognized by different PGRPs during insect innate immune responses and induce theproduction of antimicrobial peptides. Previously, our laboratory reported the recognitionmechanism and its signaling pathway of polymeric DAP-type PGN in Tenebrio molitorlarvae. However, the molecular recognition mechanism of monomeric DAP-type PGN isstill unclear. Recently, our group found a novel 17 kDa protein from Tenebrio hemolymphthat showed high sequence homology with that of Drosophila PGRP-LE. To furtherunderstand the molecular recognition mechanism of monomeric DAP-type PGN, we havetried to RNA interference experiment of Tenebrio newPGRP homolog gene(Tc-PGRP1,2)using the red flour beetle, Tribolium castaneum. we checked significant knockdown oftarget genes by injecting dsRNA and then proceeded to inject different types of PGNs. Asa result, we observed that induction of several kind of AMPs significantly decreased onlyin monomeric-DAP PGN injected Tribolium larvae but not in Lys-type PGN injected larvaeafter knockdown of PGRP.O-18-19Immune response in tenebrio molitor larvae by invasion ofacholeplasma laidlawiiSeong-Min Kang, Yeo-Jin Won, Ho-Jung Eo, Yong-In So, Dong-Jun Jung, YongHun Jo, kenji kurokawa, Bok-Luel LeeFrom the National Research Laboratory of Defense Proteins, College of Pharmacy, Pusan NationalUniversity, Busan 609-735, KoreaPeptidoglycan, a major cell wall component of bacteria, is known to trigger strong innateimmune responses in the insects and human. However, Mycoplasma species belongingto a class of Mollicutes is lack of peptidoglycan in their cell wall. However, Mycoplasmaspecies, such as Mycoplasma pneumoniae and Mycolpasma genitalium, are majorpathogen causing pneumonia in human and animals. Here, we tried to purify whichmolecule(s) of Mycoplasma species is involved in Mycoplasma-mediated pathogenesis.When we injected Acholeplasma laidlawii, which is culturable strain in the laboaratory,into coleopteran insect Tenebrio larvae larvae, antibacterial activity was induced againstEscherichia coli and Staphylococus aureus, but peptidoglyca-mediated melanin was notsynthesized. To purify the molecule showing antibacterial activities to homogeneity, weperformed several column chromatographies. Finally we obtained three moleculeseliciting antibacterial activities by C18 reverse phase HPLC. Now we are determining itsstrctures using NMR and Mass analysis.306 Korean Society for Biochemistry and Molecular Biology
Immunology
- Page 2 and 3:
SecretariatKorean Society for Bioch
- Page 4 and 5:
345710111359616498160354404Invitati
- Page 6 and 7:
General InformationRegistrationRegi
- Page 8 and 9:
Science ManagerMin-Seon KimAsan Med
- Page 10 and 11:
Tuesday, May 17, 2011Time8:00-9:00G
- Page 12 and 13:
Hall InformationSeminar | Grand Bal
- Page 14 and 15:
The poster board surface area is 95
- Page 16 and 17:
Nobel Laureate LectureMay 17 (Tue),
- Page 18 and 19:
KMA Plenary LectureMay 16 (Mon), 15
- Page 20 and 21:
Moosa Plenary LectureMay 17 (Tue),
- Page 22 and 23:
Donghun Award LectureSang-Hun LeeDe
- Page 24 and 25:
Chungsan Award LectureSue Goo RheeD
- Page 26 and 27:
Macrogen Woman Scientist Award Lect
- Page 28 and 29:
Achievement Award of Paper - BMB re
- Page 30 and 31:
Most Citation Paper Award - BMB rep
- Page 32 and 33:
Most Number of Paper Award - BMB re
- Page 34 and 35:
Merck Young Scientist Award Lecture
- Page 36 and 37:
SymposiaS1Stem Cells and Cancer Ste
- Page 38 and 39:
S3Aging and Mitochondria May 16 (Mo
- Page 40 and 41:
S5Cell Cycle and Genetic Stability
- Page 42 and 43:
S7Reactive Oxygen Species and Cell
- Page 44 and 45:
S9Stem Cell and Differentiation-KNI
- Page 46 and 47:
S11G-protein Coupled Receptors and
- Page 48 and 49:
S13Development and Model Organisms
- Page 50 and 51:
S15Innate Immunity and Host-Microbe
- Page 52 and 53:
S17Neurodevelopment and Regeneratio
- Page 54 and 55:
S19Cardiovascular Disease May 18 (W
- Page 56 and 57:
Biomedical Lecture SeriesBLS1Autoph
- Page 58 and 59:
BLS3Angiogenesis and Vascular Disea
- Page 60 and 61:
BLS5Inflammation and Immunity May 1
- Page 62 and 63:
Bio-Medical Science Co., LtdMay 17
- Page 65 and 66:
2011KSBMBAnnual MeetingStepping int
- Page 67:
KMA Plenary LectureNuclear receptor
- Page 70 and 71:
Donghun AwardStem cell biology for
- Page 72 and 73:
Stem Cells and Cancer Stem Cells, C
- Page 74 and 75:
The Early Stage of Plant Developmen
- Page 76 and 77:
Reactive Oxygen Species and Cell Si
- Page 78 and 79:
Stem Cell and Differentiation-KNIH
- Page 80 and 81:
TGF-βSignaling and Its Therapeutic
- Page 82 and 83:
Post-Transcriptional Regulation and
- Page 84 and 85:
Neurodevelopment and RegenerationS1
- Page 86 and 87:
Cardiovascular Diseaseoxidant, redu
- Page 89 and 90:
2011KSBMBAnnual MeetingStepping int
- Page 91 and 92:
Neurodegenerative Disease, Angiogen
- Page 93:
Inflammation and Immunity
- Page 96 and 97:
GE Healthcare Ltd.High content anal
- Page 99 and 100:
2011KSBMBAnnual MeetingStepping int
- Page 101 and 102:
Poster Session List
- Page 103 and 104:
Poster Session List
- Page 105 and 106:
Poster Session List
- Page 107 and 108:
Poster Session List
- Page 109 and 110:
Poster Session List
- Page 111 and 112:
Poster Session List
- Page 113 and 114:
Poster Session List
- Page 115 and 116:
Poster Session List
- Page 117 and 118:
Poster Session List
- Page 119 and 120:
Poster Session List
- Page 121 and 122:
Poster Session List
- Page 123 and 124:
Poster Session List
- Page 125 and 126:
Poster Session List
- Page 127 and 128:
Poster Session List
- Page 129 and 130:
Poster Session List
- Page 131 and 132:
Poster Session List
- Page 133 and 134:
Poster Session List
- Page 135 and 136:
Poster Session List
- Page 137 and 138:
Poster Session List
- Page 139 and 140:
Poster Session List
- Page 141 and 142:
Poster Session List
- Page 143 and 144:
Poster Session List
- Page 145 and 146:
Poster Session List
- Page 147 and 148:
Poster Session List
- Page 149 and 150:
Poster Session List
- Page 151 and 152:
Poster Session List
- Page 153 and 154:
Poster Session List
- Page 155 and 156:
Poster Session List
- Page 157 and 158:
Poster Session List
- Page 159 and 160:
Poster Session List
- Page 161 and 162:
2011KSBMBAnnual MeetingStepping int
- Page 163 and 164:
Bioinformatics and systems biology
- Page 165 and 166:
Bioinformatics and systems biology
- Page 167:
Bioinformatics and systems biology
- Page 170 and 171:
Cancer biologyB-17-01TrkC plays an
- Page 172 and 173:
Cancer biologyB-17-13Syntenin posit
- Page 174 and 175:
Cancer biologyB-17-25Role of CBR1 i
- Page 176 and 177:
Cancer biologyB-17-38Secretory leuk
- Page 178 and 179:
Cancer biologyB-17-50Thymoquinone (
- Page 180 and 181:
Cancer biologyB-17-62Omega-3 polyun
- Page 182 and 183:
Cancer biologyB-17-74Identification
- Page 184 and 185:
Cancer biologyB-17-86Elevated fibro
- Page 186 and 187:
Cancer biologyB-17-98Tissue inhibit
- Page 188 and 189:
Cancer biologyB-17-111Sox10 control
- Page 190 and 191:
Cancer biologyB-17-123Rsf-1 (HBXAP)
- Page 192 and 193:
Cancer biologyB-17-135Syndecan-2 re
- Page 194 and 195:
Cancer biologyB-17-147Involvement o
- Page 196 and 197:
Cancer biologyB-17-159Overexpressio
- Page 198 and 199:
Cancer biologyB-17-171IEX-1 is a cr
- Page 200 and 201:
Cancer biologyB-17-183Clinical vali
- Page 202 and 203:
Cell: differentiation, division and
- Page 204 and 205:
Cell: differentiation, division and
- Page 206 and 207:
Cell: differentiation, division and
- Page 208 and 209:
Cell: differentiation, division and
- Page 210 and 211:
Cell: differentiation, division and
- Page 212 and 213:
Cell: differentiation, division and
- Page 214 and 215:
Cell: differentiation, division and
- Page 216 and 217:
Cell: differentiation, division and
- Page 219 and 220:
2011KSBMBAnnual MeetingStepping int
- Page 221 and 222:
Chemical biology and drug discovery
- Page 223 and 224:
Chemical biology and drug discovery
- Page 225 and 226:
Chemical biology and drug discovery
- Page 227 and 228:
Chemical biology and drug discovery
- Page 229:
Chemical biology and drug discovery
- Page 232 and 233:
Development and regenerationE-17-01
- Page 234 and 235:
Development and regenerationE-17-13
- Page 236 and 237:
Development and regenerationE-17-25
- Page 238 and 239:
Lipids and carbohydratesF-17-01Chan
- Page 240 and 241:
MicrobiologyG-17-01Fatty acids incr
- Page 242 and 243:
MicrobiologyG-17-13MARCH5, a mitoch
- Page 244 and 245:
MicrobiologyG-17-25Discovery of che
- Page 246 and 247:
NeuroscienceH-17-01N-Adamantyl-4-me
- Page 248 and 249:
NeuroscienceH-17-12Inhibition of do
- Page 250 and 251:
NeuroscienceH-17-24Neuroprotective
- Page 252 and 253:
NeuroscienceH-17-37A novel BDNF-mod
- Page 254 and 255:
NeuroscienceH-17-49Differential alt
- Page 256 and 257:
NeuroscienceH-17-61Effect of volunt
- Page 259 and 260: 2011KSBMBAnnual MeetingStepping int
- Page 261: Plant biology
- Page 264 and 265: Protein: structure and functionJ-17
- Page 266 and 267: Protein: structure and functionJ-17
- Page 268 and 269: Protein: structure and functionJ-17
- Page 270 and 271: Protein: structure and functionJ-17
- Page 272 and 273: Biotechnology and bioengineeringK-1
- Page 274 and 275: Biotechnology and bioengineeringK-1
- Page 277 and 278: 2011KSBMBAnnual MeetingStepping int
- Page 279 and 280: Cell: signal transduction
- Page 281 and 282: Cell: signal transduction
- Page 283 and 284: Cell: signal transduction
- Page 285 and 286: Cell: signal transduction
- Page 287 and 288: Cell: signal transduction
- Page 289 and 290: Cell: signal transduction
- Page 291 and 292: Cell: signal transduction
- Page 293 and 294: 2011KSBMBAnnual MeetingStepping int
- Page 295: Cell: structure and physiology
- Page 298 and 299: Genetics and genomics, epigeneticsN
- Page 300 and 301: Genetics and genomics, epigeneticsN
- Page 302 and 303: Genetics and genomics, epigeneticsN
- Page 304 and 305: Genetics and genomics, epigeneticsN
- Page 306 and 307: ImmunologyO-18-01Cilostazol protect
- Page 310 and 311: ImmunologyO-18-26Functions of novel
- Page 312 and 313: ImmunologyO-18-39KIAA1542 gene prod
- Page 315 and 316: 2011KSBMBAnnual MeetingStepping int
- Page 317 and 318: Metabolism and metabolic diseases
- Page 319 and 320: Metabolism and metabolic diseases
- Page 321 and 322: Metabolism and metabolic diseases
- Page 323: Metabolism and metabolic diseases
- Page 326 and 327: Molecular medicine and imagingQ-18-
- Page 329 and 330: 2011KSBMBAnnual MeetingStepping int
- Page 331 and 332: Protein: modification and regulatio
- Page 333 and 334: 2011KSBMBAnnual MeetingStepping int
- Page 335: Proteomics
- Page 338 and 339: RNA biologyT-18-01Genome-wide funct
- Page 340 and 341: RNA biologyT-18-14Rapid molecular d
- Page 342 and 343: OthersU-18-01Use of non-melanocytic
- Page 344 and 345: OthersU-18-13Sulfuretin inhibits UV
- Page 346 and 347: OthersU-18-25Suppressed expression
- Page 348 and 349: OthersU-18-37Mismatch-repair relate
- Page 350 and 351: OthersU-18-49AIP2, one of AROS inte
- Page 352 and 353: Launching new technologies from the
- Page 354 and 355: KSBMB’s NEXT MEETINGSSorak Confer
- Page 356 and 357: 354Exhibition Booth Layout
- Page 358 and 359:
기기전시 상호명별 부스번
- Page 360 and 361:
(주)기산바이오텍 부스번
- Page 362 and 363:
(주)대한과학 부스번호 : 16
- Page 364 and 365:
(주)메카시스 부스번호 : 61
- Page 366 and 367:
l(주)비바젠 부스번호 : 151,
- Page 368 and 369:
(주)아토코리아 부스번호 :
- Page 370 and 371:
(주)월드사이언스 부스번
- Page 372 and 373:
천양테크 부스번호 : 38lCHUN
- Page 374 and 375:
한국바이오래드 주식회사
- Page 376 and 377:
Product Indexactivity monitoring동
- Page 378 and 379:
iochemicals고마바이오텍㈜ 10
- Page 380 and 381:
싸토리우스 코리아 바이오
- Page 382 and 383:
cuvettes, elecroporation㈜고려
- Page 384 and 385:
싸토리우스 코리아 바이오
- Page 386 and 387:
enzyme immunoassay kits고마바이
- Page 388 and 389:
㈜대명사이언스 159㈜디케
- Page 390 and 391:
implantable instrumentation서린
- Page 392 and 393:
micromanipulators㈜라이카 코
- Page 394 and 395:
㈜휴컴시스템 137oxygen uptake
- Page 396 and 397:
㈜대명사이언스 159㈜부경
- Page 398 and 399:
㈜인실리코젠 133㈜케이오
- Page 400 and 401:
한독바이오테크㈜ 64tissue c
- Page 402 and 403:
Bio Job Fair 2011May 17 ~ 18, 2011H
- Page 405 and 406:
2011KSBMBAnnual MeetingStepping int
- Page 407 and 408:
U-18-06Cho, Young Jae ……B-17-18
- Page 409 and 410:
Jang, Sei-Heon ………G-17-03Jang
- Page 411 and 412:
P-18-31, S-18-08Kim, Jeewoong …
- Page 413 and 414:
LLee, Areum …………P-18-29Lee,
- Page 415 and 416:
Moon, Yun-Won ……C-17-81Morgan,
- Page 417 and 418:
Shin, Jae-Sun ………J-17-31Shin,